Vogt-Koyanagi-Harada Syndrome: A case report and review of literature
Keywords:
Vogt-Koyanagi-Harada syndromeAbstract
Vogt-Koyanagi-Harada (VKH) syndrome is a rare multisystem disorder in which cell-mediated autoimmunity against melanocytes affects the eyes, inner ears, central nervous system and skin. Alopecia, poliosis and vitiligo are the cutaneous manifestations. Visual and hearing loss is the important complications which can be prevented by early diagnosis and aggressive systemic therapy. We report a case of VKH syndrome in which alopecia was the only cutaneous manifestation and early diagnosis and prompt systemic corticosteroid therapy prevented the visual loss and reduced the morbidity.References
Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995; 39: 265-92.
Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1980; 90: 69-75.
Walton RC. Vogt-Koyanagi-Harada Syndrome. eMedicine Journal 2001; 2.
Cunningham ET Jr, Demetrius R, Frieden IJ et al. Vogt-Koyanagi-Harada syndrome in a 4 year old child. Am J Ophthalmol 1995; 120: 675-7.
Islam SM, Numaga J, Fujino Y et al. HLA class genes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1994; 35: 3890-6.
Rao NA. Vogt-Koyanagi-Harada syndrome. Int Ophthalmol Clin 1995; 35: 69-86.
Morris WR, Schlaegel TF Jr. Viruslike inclusion bodies in subretinal fluid in uveo-encephalitis. Am J Ophthalmol 1964; 58: 940-5.
Jovic NS, Nesovic M, Vranjesevic DN et al. The Vogt-Koyanagi-Harada syndrome: association with autoimmune polyglandular syndrome type 1. Postgrad Med J 1996; 72: 495-97.
Kogiso M, Tanouchi Y, Miki S, Mimura Y. Characterization of T-cell subsets, soluble interleukin-2 receptors and interleukin-6 in Vogt-Koyanagi-Harada disease. Jap J Ophthalmol 1992; 36: 37-43.
Yokoyama MM, Matsui Y, Yamashiroya HM et al. Humoral and cellular immunity studies in patients with Vogt-Koyanagi-Harada syndrome and pars planitis. Invest Ophthalmol Vis Sci 1981; 20: 364-70.
Maezawa N, Yano A, Taniguchi M, Kojima S. The role of cytotoxic T lymphocytes in the pathogenesis of Vogt- Koyanagi-Harada disease. Ophthalmologica 1982; 185: 179-86.
Mondkar SV, Biswas J, Ganesh SK. Analysis of 87 cases with Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 2000; 44: 296-301.
Choczaj-Kukula A, Janniger CK. Vogt-Koyanagi-Harada Syndrome. eMedicine Journal 2001; 2.
Helveston WR. Treatment of Vogt-Koyanagi-Harada syndrome with intravenous immunoglobulin. Neurology 1996; 46: 584-5.
Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983; 96: 275-82.
Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol 1991; 109: 682-7.
Javed MA, Jahangir M, Sial MSH. Vogt-Koyanagi-Harada syndrome. Pak J Neurol 1998; 4:59-61.
